Management of Male Partners When a Woman Tests Positive for Trichomonas
Male partners should be presumptively treated without testing when a woman is diagnosed with trichomoniasis. 1
Rationale for Presumptive Treatment
The CDC guidelines consistently recommend treating sex partners without requiring testing, based on several key factors:
High concordance rates: Research demonstrates that 71.7% of male partners of infected women harbor T. vaginalis infection, with 77.3% of these infected men being completely asymptomatic 2
Poor follow-up compliance: Male partners have notoriously poor compliance with follow-up visits for testing and treatment, making presumptive treatment the most pragmatic approach 1
Treatment efficacy: Metronidazole regimens achieve 90-95% cure rates, and ensuring treatment of sex partners increases overall cure rates and reduces reinfection 1
Recommended Treatment Regimen for Male Partners
Metronidazole 2 g orally in a single dose is the preferred regimen 1, 3
Alternative regimen: Metronidazole 500 mg twice daily for 7 days 1
Partner Management Strategy
The guidelines explicitly state that "sex partners should be treated" as a categorical recommendation 1
Key management points:
Both patient and partner(s) must abstain from sexual activity until therapy is completed and both are asymptomatic 1
In the absence of microbiologic test-of-cure, "cured" means therapy has been completed and both partners are without symptoms 1
Expedited partner therapy (partner-delivered therapy) is an effective strategy, with studies showing lower reinfection rates when women deliver medication directly to partners 4
Common Pitfalls to Avoid
Do not wait for partner testing results before initiating treatment. The majority of infected men are asymptomatic, and delays in partner treatment lead to:
- Reinfection of the treated female partner
- Continued transmission in the community
- Poor partner follow-through with testing appointments 2, 5
Do not assume younger age predicts infection. While younger male age (20-39 years) is associated with higher infection rates, the average age of T. vaginalis-infected males (39.9 years) is significantly higher than for other STIs like chlamydia or gonorrhea 2, 6
When Testing Might Be Considered
While presumptive treatment remains the standard, testing may be useful in specific scenarios:
- When evaluating treatment failure in the female partner to exclude reinfection 1
- In research or surveillance settings to document prevalence 2, 6
- When using nucleic acid amplification tests (NAATs) on urine specimens, which offer convenient, non-invasive detection with high sensitivity 2, 3
However, testing should never delay treatment initiation 1